Impact of anti-VEGF treatment for diabetic macular oedema on progression to proliferative diabetic retinopathy: data-driven insights from a multicentre study.

ABSTRACT:

Objective

To report insights on proliferative diabetic retinopathy (PDR) risk modification with repeated antivascular endothelial growth factor (VEGF) injections for the treatment of diabetic macular oedema (DMO) in routine care.

Methods and analysis

Multicentre study (27 UK-National Health Service centres) of patients with non-PDR (NPDR) and DMO. Primary outcome was PDR development. Repeated anti-VEGF injections were modelled as time-dependent covariates using Cox regression and weighted cumulative exposure (WCE) adjusting for baseline diabetic retinopathy (DR) grade, age, sex, ethnicity, type of diabetes and deprivation. PDR incidence rates (IRs) were calculated.

Results

We included 2858 DMO anti-VEGF-treated eyes. Anti-VEGF injections showed a protective effect on

SUBMITTER: Olvera-Barrios A 

PROVIDER: S-EPMC12273153 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature